Number of shares and votes in Orexo

Uppsala, Sweden – August 30, 2013 - The number of shares and votes in Orexo AB
has changed as a result of the conversion of convertible bonds subscribed for by
Novo A/S and the exercise of warrants.

Today, the last trading day of the month, there are in total 32,532,858 shares
and votes in the company.

For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)722-20 94 77, E-mail: henrik.juuel@orexo.com

About Orexo
Orexo AB is an emerging specialty pharma company with commercial operations in
the United States and R&D in Sweden developing improved treatments using
proprietary drug delivery technology. Orexo’s expertise is within the area of
reformulation technologies and especially sublingual formulations. The company
has a portfolio of revenue generating US and EU approved products currently
marketed under licence and a pipeline of several reformulations of approved
compounds for areas of unmet medical need. Orexo also has collaboration projects
with several international pharma companies. Orexo, with its headquarters in
Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and
HealthCap.

For information about Orexo please visit www.orexo.com

Orexo is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 4:30 pm CET on August 30, 2013.